Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Goodwill (2016 - 2025)

Gsk has reported Goodwill over the past 11 years, most recently at $9.3 billion for Q4 2025.

  • Quarterly results put Goodwill at $9.3 billion for Q4 2025, up 4.17% from a year ago — trailing twelve months through Dec 2025 was $9.3 billion (up 4.17% YoY), and the annual figure for FY2025 was $9.3 billion, up 4.17%.
  • Goodwill for Q4 2025 was $9.3 billion at Gsk, up from $9.0 billion in the prior quarter.
  • Over the last five years, Goodwill for GLAXF hit a ceiling of $14.2 billion in Q4 2021 and a floor of $8.3 billion in Q4 2022.
  • Median Goodwill over the past 5 years was $9.0 billion (2024), compared with a mean of $9.8 billion.
  • Biggest five-year swings in Goodwill: crashed 41.9% in 2022 and later rose 6.01% in 2024.
  • Gsk's Goodwill stood at $14.2 billion in 2021, then crashed by 41.9% to $8.3 billion in 2022, then rose by 2.29% to $8.5 billion in 2023, then increased by 6.01% to $9.0 billion in 2024, then rose by 4.17% to $9.3 billion in 2025.
  • The last three reported values for Goodwill were $9.3 billion (Q4 2025), $9.0 billion (Q4 2024), and $8.5 billion (Q4 2023) per Business Quant data.